Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
MET Homes provides an off-the-shelf modern construction method (MMC) for housing, aiming to make MMC financially viable at lower production volumes, which addresses an identified market gap. Their system utilizes 13 pre-engineered and factory-assembled load-bearing wall and floor panels, suitable for constructing residential new builds up to three stories high. With a selection of 13 panels, MET Homes has developed over 50 house types in different widths, lengths, and roof styles, offering versatility for construction projects.
days to go:
Expired
investment:
£110,602
Capital Physio is one of the UK’s fastest growing providers of retail physiotherapy. Since inception in 2012, the group has opened 17 clinics as part of a highly scalable and growth driven business model.
days to go:
Expired
investment:
£6,210
Yodomo is a platform for creative experiences offering 100+ high-quality courses, live experiences from creative artists, and kits of materials. Backed by more than 200 investors and live experience partners including The Sunday Times, Yodomo has built a marketplace creating new revenue streams for artists via numerous courses. These include bookbinding, drawing, sewing, botany, and weaving. Its corporate clients include Innocent, Fora, and Ticketmaster. Moreover, Yodomo was nominated for Seedrs ‘Seedling of the Year’ award in 2019. With the proceeds, the company will focus on customer and revenue growth.
days to go:
Expired
investment:
£100,778
Evaclite manufactures dynamic exit signs designed to make buildings safer and save lives. The company argues that its products are 77% more visible than conventional exit signs and reduces congestion at exits by 36%. The company received the 2018 FIREX - Fire Innovation of the Year Award. It also won the Safety and Health Excellence (SHE) Award in 2019 and 2020. Evaclite counts companies like Apple, CBRE, BBC, Melia, and MetroBank amongst its clients. The company has inquiries from over a dozen countries globally with a 12-month sales opportunity pipeline of over £1.5 million. It will use 60% of the investment to build its sales team, 28% to boost its inbound marketing campaign, 7% to develop additional intellectual property, and 5% towards overhead and general costs.
days to go:
Expired
investment:
£148,736
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Verto Homes have created the Zero Carbon Smart Home. These homes create and store their own clean energy from the sun, they automatically know when and where light heat and shade are needed and they manage the energy they use so efficiently that their energy bills are almost 0.
days to go:
Expired
investment:
£1,389,280
